Drug Approval | April 14, 2025
Aurolife Pharma gets 11 observations from USFDA for Raleigh plant
The company does not expect this development to have any material impact on the current business operations
The company does not expect this development to have any material impact on the current business operations
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
_256_384.jpg)
Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
Strengthening capabilities in Peptide Therapeutics and CDMO services
The board of directors accepted Hrosz’s resignation and expressed appreciation for his significant contributions during his tenure
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Mantri will replace V. S. Mani, Executive Director & Global Chief Financial Officer of the company as he has conveyed his decision to opt for early retirement
NATCO has decided to price the product at Rs.15, 900 MRP consistent with the company’s stand before the court
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
Subscribe To Our Newsletter & Stay Updated
